Based on our findings, TG may be applied in even lower dosages (25–40% of registered dose) for IBD treatment in intermediate TPMT metabolisers to maximize safety while maintaining clinical remission and therapeutic 6-TGN concentrations. Here, TPMT is linked to inflammatory bowel disease.